Anti-obesity drugs: Are they worth it?

Future Medicinal Chemistry

Volumn 3, Issue 3, 2011, Pages 267-269

  Huntington, Mark K ^a,b   Shewmake, Roger A ^a,b  

^a Center for Family Medicine   (United States)

^b UNIVERSITY OF SOUTH DAKOTA   (United States)

Author keywords

adverse effects; cost effectiveness; efficacy; obesity; weight loss

Indexed keywords

AMFEBUTAMONE; AMINOREX; ANTIOBESITY AGENT; BETHIN; CONTRAVE; DEXFENFLURAMINE; EMPATIC; EXENDIN 4; FENFLURAMINE; FLUOXETINE; LORCASERIN; LORQESS; METERMINE; METFORMIN; MONASLIM; NALTREXONE; OBEPHEN; OBERMINE; PHENTERMINE; PHENTERMINE RESIN; PHENTROMIN; PRAMLINTIDE; PROFAST SA; QNEXA; REMONABENT; RIMONABANT; RIMOSLIM; RIOBANT; RIOMONT; SIBUTAMINE; SIBUTRAMINE; SLIMONA; SUMATRIPTAN; SUMATRIPTAN SUCCINATE; TESOFENSINE; TETRAHYDROLIPSTATIN; TOPIRAMATE; UNCLASSIFIED DRUG; ZONISAMIDE;

ANAL LEAKAGE; BOWEL MOVEMENT; CARDIOVASCULAR RISK; DIARRHEA; DRUG COST; FATTY STOOL; FLATULENCE; GASTROINTESTINAL SYMPTOM; HEART ARRHYTHMIA; HUMAN; INFARCTION; NOTE; OBESITY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SELF ESTEEM; SOFT STOOL; STROKE; VALVULAR HEART DISEASE;

ANTI-OBESITY AGENTS; HUMANS; OBESITY; WEIGHT LOSS;

EID: 79953244766     PISSN: 17568919     EISSN: None     Source Type: Journal    
DOI: 10.4155/fmc.11.5     Document Type: Note

References (16)

1. Rucker D, Padwal R, Li SK, Curioni C, Lau DC. Long term pharmacotherapy for obesity and overweight: Updated meta-analysis. BMJ 335(7631), 1194-1199 (2007). (Pubitemid 350273303)
2. O'Meara S, Riemsma R, Shirran L, Mather L, ter Riet G. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of orlistat in the management of obesity. Health Technology Assessment 5(18), 1-81 (2001).
3. Escott-Stump S. Nutrition and Diagnosis-Related Care. Lippincott Williams & Wilkins, PA, USA (2002).
4. Hill JO, Hauptman J, Anderson JW et al. Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: A 1-y study. Am. J. Clin. Nutr. 69(6), 1108-1116 (1999). (Pubitemid 29252041)
5. Mechcatie E. FDA panel gives thumbs down to lorcaserin. Family Practice News 40(17), 9 (2010).
6. Turley A. Obesity drugs strive for US approval. Chemistry World 7(9), 2 (2010).
7. Bray GA. Medications for obesity: Mechanisms and applications. Clin. Chest Med. 30(3), 525-538 (2009).
8. Huntington MK, Shewmake RA. Weight-loss supplements: what is the evidence? S. D. Med. 63(6), 205-207 (2010).
9. DeLaet D, Schauer D. Obesity in adults. Am. Fam. Physician. 82(8), 974-975 (2010).
10. Pillitteri JL, Shiffman S, Rohay JM, Harkins AM, Burton SL, Wadden TA. Use of dietary supplements for weight loss in the United States: Results of a national survey. Obesity (Silver Spring), 16(4), 790-796 (2008). (Pubitemid 351465634)
11. Blanck HM, Serdula MK, Gillespie C et al. Use of nonprescription dietary supplements for weight loss is common among Americans. J. Am. Diet. Assoc. 107(3), 441-447 (2007). (Pubitemid 46281823)
12. Pi-Sunyer X, Kris-Etherton P. Improving health outcomes: Future directions in the field. J. Am. Diet. Assoc. 105(5 Suppl. 1), S14-S16 (2005). (Pubitemid 40615751)
13. Greenway FL, Ryan DH, Bray GA, Rood JC, Tucker EW, Smith SR. Pharmaceutical cost savings of treating obesity with weight loss medications. Obes. Res. 7(6), 523-531 (1999). (Pubitemid 129710616)
14. Avenell A, Broom J, Brown TJ et al. Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement. Health Technology Assessment 8(21), 1-182 (2004).
15. Welbourn R, Pournaras D. Bariatric surgery: A cost-effective intervention for morbid obesity; functional and nutritional outcomes. Proc. Nutr. Soc. 69(4), 528-535 (2010).
16. Tsai AG, Asch DA, Wadden TA. Insurance coverage for obesity treatment. J. Am. Diet. Assoc. 106(10), 1651-1655 (2006). (Pubitemid 44415595)